ⓘ High-altitude pulmonary edema is a life-threatening form of non-cardiogenic pulmonary edema that occurs in otherwise healthy people at altitudes typically above ..


ⓘ High-altitude pulmonary edema

High-altitude pulmonary edema is a life-threatening form of non-cardiogenic pulmonary edema that occurs in otherwise healthy people at altitudes typically above 2.500 meters. However, cases have also been reported between 1.500–2.500 metres or 4.900–8.200 feet in more vulnerable subjects.

Classically, HAPE occurs in persons normally living at low altitude who travel to an altitude above 2.500 meters 8.200 feet. Re-entry HAPE is also an entity that has been described in persons who normally live at high altitude but who develop pulmonary edema after returning from a stay at low altitude.

There are many factors that can make a person more susceptible to developing HAPE, including genetic factors, but detailed understanding is lacking and currently under investigation. HAPE remains the major cause of death related to high-altitude exposure, with a high mortality rate in the absence of adequate emergency treatment.


1. Signs and symptoms

Physiological and symptomatic changes often vary according to the altitude involved.

The Lake Louise Consensus Definition for high-altitude pulmonary edema has set widely used criteria for defining HAPE symptoms.

In the presence of a recent gain in altitude, the presence of the following:

Symptoms: at least two of:

  • Shortness of breath at rest
  • Cough
  • Chest tightness or congestion
  • Weakness or decreased exercise performance

Signs: at least two of:

  • Tachycardia rapid heart rate
  • Tachypnea rapid breathing
  • Central blue skin color
  • Crackles or wheezing while breathing in at least one lung field

2. Risk factors

There are multiple factors that can contribute to the development of HAPE, including sex male, genetic factors, prior development of HAPE, ascent rate, cold exposure, peak altitude, intensity of physical exertion, and certain underlying medical conditions eg, pulmonary hypertension. Anatomic abnormalities that are predisposing include congenital absence of pulmonary artery, and left-to-right intracardiac shunts eg, atrial and ventricular septal defects, both of which increase pulmonary blood flow. HAPE-susceptible HAPE-s individuals were also found to be four times more likely to have a patent foramen ovale PFO than those who were HAPE-resistant. There is currently no indication or recommendation for people with PFO to pursue closure prior to extreme altitude exposure.

In studies performed at sea level, HAPE-s people were found to have exaggerated circulatory response to both hypoxia at rest and during exercise. In these individuals, the pulmonary artery pressure PAP and pulmonary vascular resistance PVR were shown to be abnormally high. Microneurographic recordings in these individuals developed a direct link between PAP rise and sympathetic nervous system over-activation, which could explain the exaggerated response to hypoxia in these persons.

Endothelial tissue dysfunction has also been linked to development of HAPE, including reduced synthesis of NO a potent vasodilator, increased levels of endothelin a potent vasconstrictor, and an impaired ability to transport sodium and water across the epithelium and out of the alveoli.

Data on the genetic basis for HAPE susceptibility is conflicting and interpretation is difficult. Genes implicated in the development of HAPE include those in the renin-angiotensin system RAS, NO pathway, and hypoxia-inducible factor pathway HIF. Future genomic testing could provide a clearer picture of the genetic factors that contribute to HAPE.


3. Pathophysiology

Though it remains a topic of intense investigation, multiple studies and reviews over the last several years have helped to elucidate the proposed mechanism of HAPE. The inciting factor of HAPE is the decrease in partial pressure of arterial oxygen caused by the lower air pressure at high altitudes pulmonary gas pressures. The resultant hypoxemia is then thought to precipitate the development of:

  • Increased pulmonary arterial and capillary pressures pulmonary hypertension secondary to hypoxic pulmonary vasoconstriction.
  • Increased capillary pressure hydrostatic pressure with over-distention of the capillary beds and increased permeability of the vascular endothelium, also known as "stress failure." This leads to subsequent leakage of cells and proteins into the alveoli, aka pulmonary edema.

Hypoxic pulmonary vasoconstriction HPV occurs diffusely, leading to arterial vasoconstriction in all areas of the lung. This is evidenced by the appearance of "diffuse," "fluffy," and "patchy" infiltrates described on imaging studies of climbers with known HAPE.

Although higher pulmonary arterial pressures are associated with the development of HAPE, the presence of pulmonary hypertension may not in itself be sufficient to explain the development of edema; severe pulmonary hypertension can exist in the absence of clinical HAPE in subjects at high altitude.


4. Diagnosis

The diagnosis of HAPE is entirely based on symptoms and many of the symptoms overlap with other diagnoses. Before HAPE was understood it was commonly confused with pneumonia which resulted in inappropriate treatment.

HAPE generally develops in the first 2 to 4 days of hiking at altitudes > 2.500 meters 8.200 ft, and symptoms seem to worsen most commonly on the second night. Initial symptoms are vague and include shortness of breath, decreased exercise ability, increased recovery time, fatigue, and weakness, especially with walking uphill. People then develop a dry, persistent cough, and often cyanosis of the lips. Another cardinal feature of HAPE is the rapid progression to dyspnea at rest. The development of pink, frothy, or frankly bloody sputum are late features of HAPE. In some cases, people will develop concomitant neurological features such as poor coordination, altered consciousness, or cerebral edema High-altitude cerebral edema.

On physical exam, increased breathing rates, increased heart rates, and a low-grade fever 38.5 o 101.3 o F are common. Listening to the lungs may reveal crackles in one or both lungs, often starting in the right middle lobe. This can be seen on X-ray and CT imaging of the chest. One distinct feature of HAPE is that pulse oximetry saturation levels SpO 2 are often decreased from what would be expected for the altitude. People typically do not appear as ill as SpO 2 and chest X-ray films would suggest. Giving extra oxygen rapidly improves symptoms and SpO 2 values; in the setting of infiltrative changes on chest X-ray, this is nearly pathognomonic for HAPE.


4.1. Diagnosis Differential diagnosis

Differential diagnosis:

  • Exercise-associated hyponatremia
  • Pneumonia
  • Bronchitis
  • Mucous plugging
  • Asthma
  • Acute decompensated heart failure
  • Pneumothorax
  • Reactive airway disease
  • Pulmonary embolism
  • Acute coronary syndrome

5. Prevention

The primary recommendation for the prevention of HAPE is gradual ascent. The suggested rate of ascent is the same that applies to the prevention of acute mountain sickness and high-altitude cerebral edema.

The Wilderness Medical Society WMS recommends that, above 3.000 metres 9.800 ft, climbers

  • include a rest day every 3-4 days ie, no additional ascent.
  • not increase the sleeping elevation by more than 500 metres 1.600 ft a day, and

In the event that adherence to these recommendations is limited by terrain or logistical factors, the WMS recommends rest days either before or after days with large gains. Overall, WMS recommends that the average ascent rate of the entire trip be less than 500 metres 1.600 ft per day.

The most studied and preferred medication for prevention of HAPE is nifedipine, a pulmonary vasodilator. The recommendation for its use is strongest for individuals with a history of HAPE. According to published data, treatment is most effective if given one day prior to ascent and continued for four to five days, or until descent below 2.500 meters 8.200 ft.

Additional medications that are being considered for prevention but require further research to determine efficacy and treatment guidelines include acetazolamide, salmeterol, tadalafil and other PDE5 inhibitors, and dexamethasone. Acetazoladmide has proven to be clinically effective, but formal studies are lacking. Salmeterol is considered an adjunctive therapy to nifedipine, though only in highly susceptible climbers with clearly demonstrated recurrence of HAPE. Tadalafil was found to be effective at preventing HAPE in HAPE-s individuals during rapid ascent, but optimal dosing and frequency has yet to be established. Use of dexamethasone is currently indicated for the treatment of moderate-to-severe acute mountain sickness, as well as high-altitude cerebral edema. It has also been found to prevent HAPE, but its routine use is not yet recommended.

Notably, each of these medications acts to block hypoxic pulmonary hypertension, lending evidence to the proposed pathophysiology of HAPE outlined above.


6. Treatment

The recommended first line treatment is descent to a lower altitude as quickly as possible, with symptomatic improvement seen in as few as 500 to 1.000 meters 1.640 feet to 3.281 feet. However, descent is not mandatory and treatment with warming techniques, rest, and supplemental oxygen can improve symptoms. Giving oxygen at flow rates high enough to maintain an SpO 2 at or above 90% is a fair substitute for descent. In the hospital setting, oxygen is generally given by nasal cannula or face mask for several hours until the person is able to maintain oxygen saturations above 90% while breathing the surrounding air. In remote settings where resources are scarce and descent is not feasible, a reasonable substitute can be the use of a portable hyperbaric chamber, which simulates descent, combined with additional oxygen and medications.

As with prevention, the standard medication once a climber has developed HAPE is nifedipine, although its use is best in combination with and does not substitute for descent, hyperbaric therapy, or oxygen therapy. Though they have not formally been studied for the treatment of HAPE, phosphodiesterase type 5 inhibitors such as sildenafil and tadalafil are also effective and can be considered as add-on treatment if first-line therapy is not possible; however, they may worsen the headache of mountain sickness. There is no established role for the inhaled beta-agonist salmeterol, though its use can be considered.

Dexamethasone has a potential role in HAPE, though there are currently no studies to support its effectiveness as treatment. However, as outlined in the 2014 WMS Practice Guidelines, its use is recommended for the treatment of people with concomitant HAPE and HACE at the treatment doses recommended for HACE alone. Additionally, they support its use in HAPE with neurologic symptoms or hypoxic encephalopathy that cannot be distinguished from HACE.


7. Epidemiology

Rates of HAPE differs depending on altitude. In general, there is about a 0.2 to 6 percent incidence at 4.500 metres 14.800 ft, and about 2 to 15 percent at 5.500 metres 18.000 ft. It has been reported that about 1 in 10.000 skiers who travel to moderate altitudes in Colorado develop HAPE; one study reported 150 cases over 39 months at a Colorado resort located at 2.928 metres 9.606 ft. About 1 in 50 climbers who ascended Denali. In climbers who had previously developed HAPE, re-attack rate was up to 60% with ascent to 4.559 metres 14.957 ft in a 36 hour time period, though this risk was significantly reduced with slower ascent rates.


8. Research

To help understand factors that make some individuals susceptible to HAPE, the International HAPE Database was set up in 2004. The database is administered by APEX, a high altitude medical research charity. A few cases support the possibility of reascent following recovery and acclimatization after an episode of HAPE precipitated by rapid ascent.

  • Pulmonary edema is fluid accumulation in the tissue and air spaces of the lungs. It leads to impaired gas exchange and may cause respiratory failure.
  • sickness can progress to high altitude pulmonary edema HAPE with associated shortness of breath or high altitude cerebral edema HACE with associated confusion
  • high altitude pulmonary edema HAPE or high altitude cerebral edema HACE The charity s official website Mountain sickness research High altitude pulmonary
  • High - altitude cerebral edema HACE is a medical condition in which the brain swells with fluid because of the physiological effects of traveling to a
  • ultimately leads to high altitude pulmonary edema HAPE For this reason, some climbers carry supplemental oxygen to prevent hypoxia, edema and HAPE. The
  • simulating flight. High - altitude pulmonary edema High - altitude cerebral edema Flatulence Auerbach Paul, Miller YE February 1981 High Altitude Flatus Expulsion
  • altitude illnesses such as acute mountain sickness, and the rare but rapidly fatal conditions, high - altitude pulmonary edema HAPE and high - altitude
  • Swimming induced pulmonary edema SIPE also known as immersion pulmonary edema occurs when fluids from the blood leak abnormally from the small vessels
  • used for treating severe cases of altitude sickness, high - altitude cerebral edema and high - altitude pulmonary edema Like office - based hyperbaric medicine
  • potentially fatal high - altitude pulmonary edema HAPE and high - altitude cerebral edema HACE The higher the altitude the greater the risk. Expedition doctors
  • serious illnesses such as altitude sickness, high altitude pulmonary edema and high altitude cerebral edema The higher the altitude the more likely are
  • reduced oxygen at high altitudes It causes drowsiness or loss of consciousness, leading to brain herniation and death. Pulmonary edema occurs when the